静脉-静脉体外膜氧合中的红细胞输注:一项多中心队列研究
该研究采用多中心回顾性研究与问卷调查相结合的混合方法,纳入全球16个ICU在2018年1月至2019年7月间接受静脉-静脉体外膜氧合的患者208例,63%为男性,年龄55岁(45-62岁),主要因急性呼吸窘迫综合征接受治疗。主要结局为接受红细胞输注的比例、每日及总输注量;88%患者接受至少1次红细胞输注,输注日输注量为1.6 U(1.3-2.3 U),非出血患者中该比例也达81%。体外膜氧合期间血红蛋白从10.8 g/dL(8.9-13.0 g/dL)降至8.7 g/dL(7.7-9.8 g/dL),输注日最低血红蛋白为8.1 g/dL(7.4-9.3 g/dL)。采用宽松阈值(血红蛋白>9 g/dL)的患者每个输注日和每个体外膜氧合日的总红细胞输注量更多,但不同阈值间生存率、出血及血栓并发症发生率无差异,输注与未输注患者28天死亡率相同。
要点
- 静脉-静脉体外膜氧合患者红细胞输注率高达88%,非出血患者也达81%,提示输血实践普遍宽松。
- 体外膜氧合期间血红蛋白由10.8 g/dL(8.9-13.0 g/dL)降至8.7 g/dL(7.7-9.8 g/dL),输注日最低血红蛋白为8.1 g/dL(7.4-9.3 g/dL)。
- 输注日红细胞输注量为1.6 U(1.3-2.3 U)。
- 宽松阈值(血红蛋白>9 g/dL)患者每个输注日和每个体外膜氧合日的总红细胞输注量更多,但生存率、出血及血栓并发症发生率无差异。
- 输注与未输注患者28天死亡率相同。
适用人群与场景
- 2018年1月至2019年7月间在16个ICU接受静脉-静脉体外膜氧合的患者,主要因急性呼吸窘迫综合征接受治疗。
研究设计与关键结果
- 研究设计为混合方法,结合多中心回顾性研究与问卷调查,纳入16个ICU的208例静脉-静脉体外膜氧合患者,63%为男性,年龄55岁(45-62岁),体外膜氧合持续时间9天(5-14天)。
- 主要结局:88%患者接受至少1次红细胞输注,输注日输注量为1.6 U(1.3-2.3 U);非出血患者中输血发生率为81%。
- 体外膜氧合前血红蛋白为10.8 g/dL(8.9-13.0 g/dL),体外膜氧合期间降至8.7 g/dL(7.7-9.8 g/dL);输注日最低血红蛋白为8.1 g/dL(7.4-9.3 g/dL)。
- 采用宽松阈值(血红蛋白>9 g/dL)的患者每个输注日和每个体外膜氧合日的总红细胞输注量更多。
- 不同输血阈值间生存率、出血及血栓并发症发生率无差异;输注与未输注患者28天死亡率相同。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究结合问卷调查。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论指出静脉-静脉体外膜氧合患者红细胞输注发生率高,即使非出血患者也是如此;作者认为需要未来研究来确定体外膜氧合患者的最佳输血阈值和触发因素。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: In the general critical care patient population, restrictive transfusion regimen of RBCs has been shown to be safe and is yet implemented worldwide. However, in patients on venovenous extracorporeal membrane oxygenation, guidelines suggest liberal thresholds, and a clear overview of RBC transfusion practice is lacking. This study aims to create an overview of RBC transfusion in venovenous extracorporeal membrane oxygenation.
DESIGN: Mixed method approach combining multicenter retrospective study and survey.
SETTING: Sixteen ICUs worldwide.
PATIENTS: Patients receiving venovenous extracorporeal membrane oxygenation between January 2018 and July 2019.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was the proportion receiving RBC, the amount of RBC units given daily and in total. Furthermore, the course of hemoglobin over time during extracorporeal membrane oxygenation was assessed. Demographics, extracorporeal membrane oxygenation characteristics, and patient outcome were collected. Two-hundred eight patients received venovenous extracorporeal membrane oxygenation, 63% male, with an age of 55 years (45-62 yr), mainly for acute respiratory distress syndrome. Extracorporeal membrane oxygenation duration was 9 days (5-14 d). Prior to extracorporeal membrane oxygenation, hemoglobin was 10.8 g/dL (8.9-13.0 g/dL), decreasing to 8.7 g/dL (7.7-9.8 g/dL) during extracorporeal membrane oxygenation. Nadir hemoglobin was lower on days when a transfusion was administered (8.1 g/dL [7.4-9.3 g/dL]). A vast majority of 88% patients received greater than or equal to 1 RBC transfusion, consisting of 1.6 U (1.3-2.3 U) on transfusion days. This high transfusion occurrence rate was also found in nonbleeding patients (81%). Patients with a liberal transfusion threshold (hemoglobin > 9 g/dL) received more RBC in total per transfusion day and extracorporeal membrane oxygenation day. No differences in survival, hemorrhagic and thrombotic complication rates were found between different transfusion thresholds. Also, 28-day mortality was equal in transfused and nontransfused patients.
CONCLUSIONS: Transfusion of RBC has a high occurrence rate in patients on venovenous extracorporeal membrane oxygenation, even in nonbleeding patients. There is a need for future studies to find optimal transfusion thresholds and triggers in patients on extracorporeal membrane oxygenation.
参考来源
- Raasveld SJ, Karami M, van den Bergh WM, et al. RBC Transfusion in Venovenous Extracorporeal Membrane Oxygenation: A Multicenter Cohort Study. Crit Care Med. 2022. PMID: 35100195. doi:10.1097/CCM.0000000000005398
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。